Last 24 Hours
Last 24 Hours: Trispecific Antibodies, Pan-RAS Commercial Surges, and TCR Biologics (2026-11-06)
Clinical trial disclosures for trispecific antibodies, a record $198M launch for pan-RAS inhibitor Rasonque, and over $220M in venture capital for intracellular TCRs and MPN clonal drivers headline the latest 24 hours in biotech.